04:13 PM EDT, 05/12/2025 (MT Newswires) -- Xenon Pharmaceuticals ( XENE ) reported a Q1 net loss late Monday of $0.83 per diluted share, widening from a loss of $0.62 a year earlier.

Analysts polled by FactSet expected a loss of $0.91.

Revenue for the three months ended March 31 was $7.5 million, compared with nil a year earlier. Analysts expected $2.2 million.

Based on current operating plans, Xenon said it anticipates having sufficient cash to fund operations into 2027.

Shares of the company were down more than 13% in recent after-hours activity.